Russia has announced the development of a groundbreaking mRNA-based cancer vaccine named Enteromix, which has shown high efficacy in preclinical trials.
The vaccine was developed by the National Medical Research Radiological Centre in collaboration with the Engelhardt Institute of Molecular Biology, and was unveiled by Veronika Skvortsova, head of the Federal Medical and Biological Agency (FMBA), during the Eastern Economic Forum.
According to Skvortsova, preclinical trials demonstrated tumor reduction rates between 60% and 80%, with some test subjects experiencing complete tumor regression. Importantly, no serious side effects were reported during the trials.
Enteromix is designed as a personalized treatment, using artificial intelligence to tailor the vaccine to each patient’s specific cancer profile. Initially targeting colorectal cancer, it holds promise for treating various other forms of the disease.
Once approved, the vaccine will be distributed free of charge across Russia, marking a potentially transformative step in the country’s fight against cancer.
Medical experts have hailed the development as a significant leap forward in oncology and personalized medicine.
